Mostrar el registro sencillo del ítem
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
| dc.contributor.author | Redin, E. | |
| dc.contributor.author | Garmendia, I. | |
| dc.contributor.author | Lozano, T. | |
| dc.contributor.author | Serrano, D. | |
| dc.contributor.author | Senent, Y. | |
| dc.contributor.author | Redrado, M. | |
| dc.contributor.author | Villalba, M. | |
| dc.contributor.author | De Andrea, C. E. | |
| dc.contributor.author | Exposito, F. | |
| dc.contributor.author | Ajona, D. | |
| dc.contributor.author | Ortiz Espinosa, S. | |
| dc.contributor.author | Remirez, A. | |
| dc.contributor.author | Bertolo, C. | |
| dc.contributor.author | Sainz, C. | |
| dc.contributor.author | García Pedrero, Juana María | |
| dc.date.accessioned | 2021-11-09T07:33:23Z | |
| dc.date.available | 2021-11-09T07:33:23Z | |
| dc.date.issued | 2021 | |
| dc.identifier.citation | Journal for ImmunoTherapy of Cancer, 9(3) (2021); doi:10.1136/jitc-2020-001496 | |
| dc.identifier.issn | 2051-1426 | |
| dc.identifier.uri | http://hdl.handle.net/10651/60933 | |
| dc.description.sponsorship | This work has been funded by the Foundation for Applied Medical Research, ISCIII-Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional 'Una manera de hacer Europa' (PI19/00230 to AC, PI19/00098 to LMM, PI17/00411 to RP and DA, PI19/00560 to JMGP; CIBERONC CB16/12/00443 to LMM and CB16/12/00390 to JMGP), AECC and Ramón Areces Foundations (both to LMM), 'Instituto de Investigación Sanitaria del Principado de Asturias to JMGP and BMS (to JA and LMM). | |
| dc.description.statementofresponsibility | Redin, E., Garmendia, I., Lozano, T., Serrano, D., Senent, Y., Redrado, M., Villalba, M., De Andrea, C.E., Exposito, F., Ajona, D., Ortiz-Espinosa, S., Remirez, A., Bertolo, C., Sainz, C., Garcia-Pedrero, J., Pio, R., Lasarte, J., Agorreta, J., Montuenga, L.M., Calvo, A. | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Journal for ImmunoTherapy of Cancer | |
| dc.rights | © 2021 Los autores | |
| dc.rights | CC Reconocimiento - No Comercial 4.0 | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
| dc.source | Scopus | |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102052429&doi=10.1136%2fjitc-2020-001496&partnerID=40&md5=fa5452e57cc27fa58db4dc7179ac0045 | |
| dc.title | SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation | |
| dc.type | journal article | |
| dc.identifier.doi | 10.1136/jitc-2020-001496 | |
| dc.relation.projectID | ISCIII/PI19/00230 | |
| dc.relation.projectID | ISCIII/PI19/00098 | |
| dc.relation.projectID | ISCIII/PI17/00411 | |
| dc.relation.projectID | ISCIII/PI19/00560 | |
| dc.relation.projectID | ISCIII/CB16/12/00443 | |
| dc.relation.publisherversion | http://dx.doi.org/10.1136/jitc-2020-001496 | |
| dc.rights.accessRights | open access | |
| dc.type.hasVersion | VoR |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos [36307]
-
Cirugía y Especialidades Médico Quirúrgicas [298]
-
Investigaciones y Documentos OpenAIRE [7936]
Publicaciones resultado de proyectos financiados con fondos públicos
Este ítem está sujeto a una licencia Creative Commons